Ribo Life-B (06938.HK) Soars 29.38% on Hong Kong Debut, Highlighting Leadership in Small Nucleic Acid Therapeutics

According to the Zhicheng Finance APP, Ribo Life Science-B (06938) made its debut on the stock market. The announcement shows that the price per share is set at HK$57.97, with a total of 31.6104 million shares issued. Each lot consists of 200 shares, and the net proceeds amount to approximately HK$1.702 billion. As of press time, the stock price surged by 29.38%, reaching HK$75, with a turnover of HK$249 million.

Public information shows that Ribo Life Science is a biopharmaceutical company engaged in the research and development of small nucleic acid drugs, with a particular focus on siRNA therapies. The company has a core product, RBD4059 (an siRNA targeting FXI), for the treatment of thrombotic diseases. Its R&D pipeline includes seven self-developed drug assets in clinical trial stages, covering seven indications related to cardiovascular, metabolic, kidney, and liver diseases, four of which are currently in Phase 2 clinical trials.

In addition to the core product RBD4059, the company is also advancing other clinical-stage products, including RBD5044 and RBD1016. RBD5044 is the world's second siRNA drug targeting APOC3 (a protein involved in lipid metabolism) to enter clinical development. RBD1016 aims to achieve functional cure for CHB by acting on HBsAg and is also a differentiated siRNA candidate drug targeting CHD. Beyond the clinical pipeline, the company has over 20 preclinical projects that are planned to be advanced into clinical development.